Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Ecancermedicalscience|July 18, 2024
Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in PeruIris Otoya, Natalia Valdiviezo, Katia Roque, et al.
Thoracic Cancer|December 28, 2020
Epidemiology of thymic epithelial tumors: 22-years experience from a single-institutionPatricia Rioja, Rossana Ruiz, Marco Galvez-Nino, et al.
International Journal of Breast Cancer|July 4, 2024
Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast CancerIris Otoya, Natalia Valdiviezo, Zaida Morante, et al.
Case Reports in Oncological Medicine|January 12, 2026
Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term SurvivalKatia Roque, Rossana Ruiz, Renier Cruz, et al.
The Breast Journal|November 24, 2025
Influence of HER2 Changes on Survival Outcomes After Neoadjuvant Chemotherapy in Peruvian Patients With Triple-Negative Breast CancerZaida Morante, Yomali Ferreyra, Iris Otoya, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapyEdurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
The New England Journal of Medicine|November 8, 2023
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
Cancer Treatment and Research Communications|March 27, 2025
Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysisMarco Galvez-Nino, Katia Roque, Rossana Ruiz, et al.
The New England Journal of Medicine|October 17, 2025
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Pageof 2